trending Market Intelligence /marketintelligence/en/news-insights/trending/n7g8cF9Jx35UsYzRM2Uo0A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Portola Pharmaceuticals prices $225M public offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Portola Pharmaceuticals prices $225M public offering

Portola Pharmaceuticals Inc. priced and upsized a previously announced common stock offering.

The company is offering 8,035,715 common shares at $28 apiece to raise $225 million, $25 million more than originally planned. The offering is expected to close by Aug. 16.

Goldman Sachs & Co. LLC, Citigroup, Cowen and William Blair are the joint book-running managers for the offering while Oppenheimer & Co. Inc. is the lead manager.

The South San Francisco, Calif.-based biopharmaceutical company gave the underwriters a 30-day option to purchase an additional 1,205,357 common shares at the same price.